Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced on December 11, 2020, that its compensation committee granted stock options and restricted stock units to two new employees.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced on December 11, 2020, that its compensation committee granted stock options and restricted stock units to two new employees. A total of 28,500 stock options were awarded, priced at $4.88 per share, alongside 14,250 restricted stock units. Both grants vest over four years and are issued under the 2016 Inducement Plan to attract new talent.
This initiative aims to enhance the company's ability to deliver innovative therapies for neurological diseases.
Positive
- Attracting new talent through stock options and restricted stock units.
- Alignment of employee interests with company performance.
Negative
- None.
Details
News Market Reaction – ADMS
The recorded move for ADMS in the trading session of this news was -0.82%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 28,500 shares of the company’s common stock, at a per share exercise price of
About Adamas Pharmaceuticals, Inc.
At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.
Contact:
Investors:
Peter Vozzo
Westwicke Partners
443-213-0505
peter.vozzo@westwicke.com
Media:
Sarah Mathieson
Vice President, Communications & Engagement
510-450-3528
smathieson@adamaspharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.